The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience

<div>Remission at 6 months separated by group following infliximab therapeutic drug monitoring in inflammatory bowel disease patients with concerns for loss of response.</div>

Canadian Journal of Gastroenterology and Hepatology

fig3

Figure 3

Figure 3: The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience 

Figure 3 | The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience 